Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells
about
In vitro comparison of antiviral drugs against feline herpesvirus 1Nucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivativesAnti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newbTenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionTenofovir disoproxil fumarate.Nucleotide binding to human UMP-CMP kinase using fluorescent derivatives -- a screening based on affinity for the UMP-CMP binding site.Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells.In search of a selective antiviral chemotherapy.Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovirIn Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.Nucleoside 5'-triphosphates: self-association, acid-base, and metal ion-binding properties in solution.Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells.Comparison of the π-stacking properties of purine versus pyrimidine residues. Some generalizations regarding selectivity.Liquid oral suspension adefovir dipivoxil (GS-02-526): an update on treatments for hepatitis B infection.Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.5',6'-nucleoside phosphonate analogues architecture: synthesis and comparative evaluation towards metabolic enzymes.Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent.Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.Molecular imprinting of AMP by an ionic-noncovalent dual approach.Formation of ternary complexes by coordination of (diethylenetriamine)-platinum(II) to N1 or N7 of the adenine moiety of the antiviral nucleotide analogue 9.Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine.Quantification of isomeric equilibria formed by metal ion complexes of 8-[2-(phosphonomethoxy)ethyl]-8-azaadenine (8,8aPMEA) and 9-[2-(phosphonomethoxy)ethyl]-8-azaadenine (9,8aPMEA). Derivatives of the antiviral nucleotide analogue 9-[2-(phosphonomAcyclic phosphonate nucleotides and human adenylate kinases: impact of a borano group on alpha-P position.Determination of adefovir in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study.Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.Impact of 9-(2-phosphonylmethoxyethyl)adenine on (deoxy)ribonucleotide metabolism and nucleic acid synthesis in tumor cellsRole of tenofovir in the treatment of chronic HBV infectionVibrational Spectroscopic Studies of Tenofovir Using Density Functional Theory Method
P2860
Q21203584-99F212D2-9568-42F1-B961-657B668F2C40Q27660045-535F2AEC-CDE6-4D72-B1B2-B28093FAFC3EQ28379404-961B0188-48DF-4BDD-B259-4FC2D07924DEQ28379497-1737EC23-0014-409D-933E-8E458D89F72DQ28379501-E9A8D55E-D6D4-4390-8B99-2B9C56E84D0AQ28571788-B5B8C1FB-8B59-4B89-88A3-B449339AFD8BQ34045308-D083D758-ACBC-42BF-B207-75A2BFF13504Q34239688-D6A99595-6BD9-4F05-BED8-DB042C97B42CQ34481359-39A0CAB5-1560-4B7F-80CE-66F9FC010751Q34534058-175B4EC4-4FBD-443D-9F4A-2EBFF920B704Q34645464-D09DB765-2FD3-4D17-B266-2C2418A09784Q35036745-0FE1AC56-08AC-4728-BA53-D55F295B6A78Q35375912-3E7CD839-5E93-4FD2-95D6-D315CA9DC385Q35912746-B1CC8DF4-48AC-445D-A98A-158AF6C1FBB6Q36075908-59AF385B-12E6-4A71-83D9-B8E934045BEDQ36106256-2091CC83-B6A0-40D6-9D4D-3F8F2134C3FFQ36261675-1986CA35-F050-44E0-BBF3-2F79187E2286Q36275141-38549ABD-8DEE-45E0-873D-4465BB3234B1Q37598750-441E9067-9968-4CDA-B87E-807C29311199Q38181953-F803F962-8081-4BB2-A75B-641CF126250EQ38220090-D55CBEBA-0548-4375-AF34-5A648852F8A5Q39471555-717FC84F-1003-4C79-8ABC-BE33C50C5CB8Q39543558-B3CAA199-4909-4079-9878-6D787DFBF662Q39557921-D7234EC2-F396-4625-B307-AFB36A7FC422Q40785692-564A889A-315A-45D2-A47A-45E00636DBCDQ41915160-87728DB4-895C-4FA1-BAF3-FDDA70658886Q41984465-E88B5AC9-C2E6-44F8-A0C5-8536B5638951Q43279341-0BA4D56A-2EBD-43BA-B9A2-81A1CF9E06F3Q43639401-49752B6F-AA68-4449-A502-6741AED6832CQ43741889-AE4DB488-1F1E-4073-8F5E-EBD51ABA5712Q45122931-32020279-462B-4843-87D2-275070F859E9Q46650637-0D613C92-295D-423F-ACF1-B4B191AAE207Q46707015-2987F144-176D-4047-BC59-329E972C7486Q52594148-6C7F3145-0337-46AB-94C2-EE5737754272Q56786482-2EB8A4A9-3F6E-4FA1-BEEC-A1D5E142E6B5Q58098975-3589B9C7-B497-4991-B443-930CFDEFDFDCQ59008777-EACE1EE5-B702-4D52-90AE-26A2DBC19687
P2860
Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells
description
1995 nî lūn-bûn
@nan
1995 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Metabolic pathways for activat ...... denine in human lymphoid cells
@ast
Metabolic pathways for activat ...... denine in human lymphoid cells
@en
type
label
Metabolic pathways for activat ...... denine in human lymphoid cells
@ast
Metabolic pathways for activat ...... denine in human lymphoid cells
@en
prefLabel
Metabolic pathways for activat ...... denine in human lymphoid cells
@ast
Metabolic pathways for activat ...... denine in human lymphoid cells
@en
P2093
P2860
P356
P1476
Metabolic pathways for activat ...... denine in human lymphoid cells
@en
P2093
A Fridland
B L Robbins
J Greenhaw
M C Connelly
P2860
P304
P356
10.1128/AAC.39.10.2304
P407
P577
1995-10-01T00:00:00Z